Buyers price a CRO or laboratory on how much of its earnings will repeat. Sponsor concentration, backlog quality and accreditation move your multiple more than revenue does. We do not print one number for this sector because the honest range depends on your service line, so run the free Exit Audit to see where your firm sits.
What is a CRO or laboratory services firm worth in 2026?
Your firm is worth a multiple of its adjusted earnings. Buyers usually quote that as a multiple of EBITDA, which means earnings before interest, taxes, depreciation and amortization. Two firms with the same EBITDA can sell at very different multiples, and the gap comes from how repeatable the earnings look.
In this sector, buyers ask three questions. Who pays you? How firmly are they committed? What happens to the work if a key scientist, a sponsor or an accreditation walks away? Your answers set the multiple.
Contract research, clinical testing and specialty labs have different business models, so a broad sector multiple may not reflect your firm. A useful valuation range needs to account for your service line, adjusted earnings, sponsor mix and backlog quality. Our free Exit Audit helps you understand how those factors affect your firm's value.
Which factors move the multiple most?
Five factors do most of the work.
Sponsor concentration: the share of revenue that comes from your largest sponsors. Less is better.
Backlog and book-to-bill: signed work not yet delivered, and the ratio of new orders to revenue delivered. A ratio above one means your backlog is growing.
Therapeutic or technical focus: specialist capability that sponsors struggle to replace draws more interest than commodity testing.
People: scientists and quality staff are the product. Buyers check who is under agreement and who could leave.
Accreditation and compliance record: the standards that apply to your work, such as CAP or CLIA where relevant, and a clean inspection history.
How does sponsor concentration change what a buyer pays?
If one sponsor accounts for a large share of your revenue, a buyer sees a single point of failure. They will ask for the master services agreement, the termination clauses and the story of how you won the work.
Concentration costs you something. The size of the discount depends on contract terms, not on how warm the relationship feels. A sponsor that has awarded you repeat studies under a framework agreement is a very different asset from one that awards project by project.
You can improve the picture before you go to market. Show repeat awards by sponsor, break revenue out by contract and show the new sponsors you have added. If your largest relationship rests on one person at your firm, say so early and show how the work would continue without that person.
Why do backlog and book-to-bill matter so much?
Backlog is the closest thing to visibility a buyer gets. It tells them how much revenue is already signed, and how much risk sits in the next several quarters.
Backlog quality varies. Work a sponsor can cancel on short notice counts for less than work under firm commitments. Early-stage studies that slip count for less than work with a clear schedule. Buyers read the detail, so we prepare it with you before they ask.
Book-to-bill shows direction. If new orders keep pace with the work you deliver, backlog holds. If they fall behind, buyers assume earnings will follow. Show the trend over several quarters, not one.
What do accreditation and regulatory standing add?
Accreditation is capacity a buyer cannot build overnight. A lab with the right accreditations, a working quality system and a clean inspection history lets a buyer serve sponsors on day one. That is worth paying for.
Buyers read the scope of each accreditation to see which revenue it protects. They also ask how a change of ownership affects it. Some accrediting bodies need to be told about ownership or key-personnel changes, so check yours early and build the answer into your plan.
Open audit findings matter too. Close them before you go to market, and keep the paper trail.
Who buys CROs and laboratories, and what do they pay for?
Three groups buy firms like yours. Each prices a little differently and structures the deal in its own way.
| Buyer type | What they pay for | What to check in the offer |
|---|---|---|
| Strategic buyer (a larger CRO or lab group) | Capacity, accreditations, sponsor relationships and specialist staff | Whether your sponsors and staff are kept, and how much of the price depends on future performance |
| Fund-backed platform | A firm that adds capability or geography to a group it is building | Earn-outs, rollover equity terms and working capital adjustments |
| Management or individual buyer | A stable lab with a clear handover | Financing certainty and how long you must stay |
The headline price is only half the story. Watch for terms that punish you after signing: tricky earn-outs, large holdbacks and unsavoury working capital adjustments. We compare offers on net proceeds, not on the number at the top of the page.
How should you prepare before going to market?
70% of businesses that go to market never sell. Preparation is how you stay out of that group.
Break revenue out by sponsor and contract, with end dates and renewal history.
Normalize your EBITDA. List every owner expense and one-off cost, and document each add-back.
Pull together backlog by sponsor, with cancellation terms.
Put key scientists and quality staff under agreements where you can.
Close open audit findings, and gather your accreditation scopes and inspection reports.
Do this before a buyer asks. Buyers who find gaps late use them to lower the price.
Questions founders ask us
What multiple should I expect for my CRO or lab?
It depends on your service line, sponsor mix, backlog and accreditations. Anyone quoting a single number without seeing your financials is guessing. Our free Exit Audit gives you a range built from your own figures.
Will my biggest sponsor stop me from selling?
No. It changes the price and the structure, not whether you can sell. Buyers want to see contract terms and repeat awards, so we show them before they ask.
Do I need every accreditation in place before I sell?
Not every one, but the ones your work depends on. Missing or lapsing accreditations are the first thing a buyer prices in. Fix what you can before you go to market.
How do I keep a sale confidential from sponsors and staff?
Confidentiality is a procedure. We use a code name and a teaser, and every buyer signs an NDA before they learn who you are. We also plan who hears about the sale, and when.
How long does a sale take, and what does it cost?
Most sales take months, not weeks, and anyone promising a closing date is guessing. We guarantee our method, not the market. We state our fee on the first call: a success fee at closing, with a small upfront fee credited against it.
Related reading
Our EBITDA multiples by industry guide: the cross-sector view of what businesses sell for.
Healthcare practice valuation multiples: how buyers value neighbouring healthcare businesses.
SDE vs EBITDA: which earnings measure applies to your company.
How to find the right M&A advisor: what to ask before you hire one.
The exit planning guide: a step-by-step checklist for preparing your business for sale.
Know your number before a buyer tells you.
Our free Exit Audit shows your number, the gaps that cost you and the buyers who would pay for your company. After $250M+ in completed transactions, we know what buyers look for. Then you decide.
FREE · CONFIDENTIAL · NO OBLIGATION
You are going to sell this once. Do it with your eyes open.